Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Molecules ; 28(3)2023 Jan 27.
Article in English | MEDLINE | ID: mdl-36770905

ABSTRACT

Amaryllidaceae alkaloids are secondary metabolites with interesting medicinal properties. Almost every Narcissus species can synthesize them and constitute an excellent source for their isolation and study. Several Amaryllidaceae alkaloids have shown acetylcholinesterase inhibitory activities and are a promising tool for treating cholinergic disorders such as Alzheimer's disease (AD). Indeed, three of the four palliative treatments approved for AD are acetylcholinesterase (AChE) inhibitors and one of them, galanthamine, is an Amaryllidaceae alkaloid itself. This molecule is currently isolated from natural sources. However, its production is insufficient to supply the increasing demand for the active principle. Our main aim is to discover tools to improve galanthamine production and to prospect for potential new and more efficient drugs for AD treatment. Furthermore, we seek to broaden the knowledge of plants of the genus Narcissus from a chemotaxonomic perspective. Hence, in this study, we evaluate the alkaloid content through GC-MS and the AChE inhibitory activity of ten autumn-flowering Narcissus, which have been less studied than their spring-flowering counterparts. A total of thirty Amaryllidaceae alkaloids have been found, twenty-eight properly identified. Two Narcissus contained galanthamine, and seven were able to inhibit AChE.


Subject(s)
Amaryllidaceae Alkaloids , Amaryllidaceae , Narcissus , Acetylcholinesterase/metabolism , Alzheimer Disease/drug therapy , Amaryllidaceae/chemistry , Amaryllidaceae Alkaloids/pharmacology , Cholinesterase Inhibitors , Galantamine/pharmacology , Narcissus/chemistry
2.
Psychiatry Investig ; 20(12): 1112-1125, 2023 Dec.
Article in English | MEDLINE | ID: mdl-38163650

ABSTRACT

OBJECTIVE: To find the safety of long-acting injectable antipsychotics (LAIs) compared to each other, and/or placebo in the treatment of schizophrenia (SCZ) and/or schizoaffective disorder (SZA). METHODS: We performed a systematic review and a network meta-analysis of randomized controlled trials (RCTs) comparing the safety of LAIs versus other LAIs or placebo in adults diagnosed with SCZ or SZA. The primary outcomes were treatment emergent adverse events (TEAEs), serious treatment emergent adverse events (STEAEs), and deaths. The secondary outcomes included treatment discontinuations due to adverse events and all-cause discontinuations. RESULTS: Seventeen RCTs were included (n=7,908). There were no significant differences between LAIs and placebo in the risk of presenting TEAEs. LAIs had a significant lower risk of presenting STEAEs except for aripiprazole. No significant differences in deaths were found. LAIs showed a significant protective effect against all-cause discontinuation, except for haloperidol. Only aripiprazole had a significantly lower risk of treatment discontinuation due to adverse events. CONCLUSION: We found no significant differences in the risk of presenting TEAEs between LAIs and placebo. The majority of LAIs had a significantly lower risk of presenting STEAEs than placebo. Development of international guidelines for the report of safety outcomes related to antipsychotics especially for LAIs in clinical trials could minimize report and interpretation biases and improve the accuracy of posterior meta-analysis.

3.
Polymers (Basel) ; 11(9)2019 Sep 11.
Article in English | MEDLINE | ID: mdl-31514277

ABSTRACT

In this work, a quantitative spectroscopic study of the bleaching phenomena occurring in plasticized formulations containing poly(vinyl chloride) was performed, proposing a general methodology to comparatively analyze the effect of degrading conditions on the polyene accumulation behaviors (PABs) exhibited by a set of tested formulations. In the study, a set of environmental indexes (temperature (T*), UV energy (UV*), and days with rain) were proposed, which allowed for the suitable globalization of the changing environmental conditions occurring throughout the different degrading periods. A procedure to numerically describe the PAB, followed by each formulation undergoing each degrading condition was also proposed, which required only two primary fitting parameters and four secondary fitting parameters. Then, the combined effects of certain environmental conditions on the PABs were studied, quantifying the stabilizing effects of the rain and the combined decrement on the T* and UV* indexes. Finally, on the basis of the proposed fitting equation and the values of its fitting parameters, the relative importance of the dehydrochlorination reactions as compared with the photo-oxidative reactions simultaneously occurring in the studied systems was estimated.

4.
Cell Biochem Biophys ; 76(3): 433-439, 2018 Sep.
Article in English | MEDLINE | ID: mdl-30003432

ABSTRACT

Acute coronary syndrome (ACS) is the leading cause of death in elderly patients worldwide. Due its participation in apoptosis, fibrosis, and angiogenesis, transforming growth factor-ß (TGF-ß) isoforms had been categorized as risk factors for cardiovascular diseases. However, due their contradictory activities, a cardioprotective role has been suggested. The aim was to measure the plasma levels of TGF-ß1, 2, and 3 proteins in patients with ACS. This was a case-control study including 225 subjects. The three activated isoforms were measured in serum using the Bio-Plex Pro TGF-ß assay by means of magnetic beads; the fluorescence intensity of reporter signal was read in a Bio-Plex Magpix instrument. We observed a significant reduction of the three activated isoforms of TGF-ß in patients with ACS. The three TGF-ß isoforms were positively correlated with each other in moderate-to-strong manner. TGFß-2 was inversely correlated with glucose and low-density lipoprotein (LDL)-cholesterol, whereas TGF-ß3 was inversely correlated with the serum cholesterol concentration. The production of TGF-ß1, TGF-ß2, and TGF-ß3 are decreased in the serum of patients with ACS. Further follow-up controlled studies with a larger sample size are needed, in order to test whether TGF-ß isoforms could be useful as biomarkers that complement the diagnosis of ACS.


Subject(s)
Acute Coronary Syndrome/pathology , Transforming Growth Factor beta/blood , Acute Coronary Syndrome/metabolism , Adult , Aged , Biomarkers/blood , Case-Control Studies , Cholesterol/blood , Cholesterol, LDL/blood , Female , Humans , Male , Middle Aged , Protein Isoforms/blood , Protein Isoforms/metabolism , Transforming Growth Factor beta/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...